BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29211618)

  • 1. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
    Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
    Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group.
    Ehrlich P; Chi YY; Chintagumpala MM; Hoffer FA; Perlman EJ; Kalapurakal JA; Warwick A; Shamberger RC; Khanna G; Hamilton TE; Gow KW; Paulino AC; Gratias EJ; Mullen EA; Geller JI; Grundy PE; Fernandez CV; Ritchey ML; Dome JS
    Ann Surg; 2017 Sep; 266(3):470-478. PubMed ID: 28795993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
    Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
    Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2.
    Benedetti DJ; Renfro LA; Tfirn I; Daw NC; Kalapurakal JA; Ehrlich PF; Khanna G; Perlman E; Warwick A; Gow KW; Paulino AC; Seibel NL; Grundy P; Fernandez CV; Geller JI; Mullen EA; Dome JS
    Cancer; 2024 Jul; 130(13):2361-2371. PubMed ID: 38396300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group.
    Hamilton TE; Ritchey ML; Haase GM; Argani P; Peterson SM; Anderson JR; Green DM; Shamberger RC
    Ann Surg; 2011 May; 253(5):1004-10. PubMed ID: 21394016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral Wilms tumor with anaplasia: A report from the Children's Oncology Group Study AREN0534.
    Romao RLP; Aldrink JH; Renfro LA; Mullen EA; Murphy AJ; Brzezinski J; Malek MM; Benedetti DJ; Cost NG; Smith E; Dome JS; Davidoff AM; Treece A; Parsons LN; Fernandez CV; Tornwall B; Shamberger RC; Paulino A; Kalapurakal JA; Geller JI; Ehrlich PF
    Pediatr Blood Cancer; 2024 Jul; 71(7):e30981. PubMed ID: 38637871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.
    Dome JS; Graf N; Geller JI; Fernandez CV; Mullen EA; Spreafico F; Van den Heuvel-Eibrink M; Pritchard-Jones K
    J Clin Oncol; 2015 Sep; 33(27):2999-3007. PubMed ID: 26304882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram for personalized prognostic assessment of children with favorable histology Wilms tumor: A retrospective analysis.
    Wang Z; Li J; Liu P; Xie X; Song H; Zhang W
    Urol Oncol; 2024 Jun; 42(6):178.e1-178.e10. PubMed ID: 38522976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2.
    Lovvorn HN; Renfro LA; Benedetti DJ; Kotagal M; Phelps HM; Ehrlich PF; Lo AC; Sandberg JK; Treece AL; Gow KW; Glick RD; Davidoff AM; Cost NG; Dix DB; Fernandez CV; Dome JS; Geller JI; Mullen EA
    J Am Coll Surg; 2024 Apr; 238(4):733-749. PubMed ID: 38251681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
    Benedetti DJ; Varela CR; Renfro LA; Tornwall B; Dix DB; Ehrlich PF; Glick RD; Kalapurakal J; Perlman E; Gratias E; Seibel NL; Geller JI; Khanna G; Malogolowkin M; Grundy P; Fernandez CV; Dome JS; Mullen EA
    Cancer; 2024 Mar; 130(6):947-961. PubMed ID: 37933882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
    Madanat-Harjuoja LM; Renfro LA; Klega K; Tornwall B; Thorner AR; Nag A; Dix D; Dome JS; Diller LR; Fernandez CV; Mullen EA; Crompton BD
    J Clin Oncol; 2022 Sep; 40(26):3047-3056. PubMed ID: 35580298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor.
    Green DM
    J Clin Oncol; 2020 Mar; 38(7):772-773. PubMed ID: 31951492
    [No Abstract]   [Full Text] [Related]  

  • 14. Considerations in the Diagnosis and Management of Pediatric Patients With Favorable Histology Wilms Tumor Who Present With Only Pulmonary Nodules.
    Green DM
    Pediatr Blood Cancer; 2016 Apr; 63(4):589-92. PubMed ID: 26626261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omission of adjuvant chemotherapy in patients with completely necrotic Wilms tumor stage I and radiotherapy in stage III: The 30-year SIOP-RTSG experience.
    Vujanić GM; Graf N; D'Hooghe E; Pritchard-Jones K; Bergeron C; Tinteren HV; Furtwängler R;
    Pediatr Blood Cancer; 2024 Mar; 71(3):e30852. PubMed ID: 38185745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Wilms tumor therapy in Lilongwe, Malawi, 2016-2021: Successes and ongoing research priorities.
    Holmes DM; Matatiyo A; Mpasa A; Huibers MHW; Manda G; Tomoka T; Mulenga M; Namazzi R; Mehta P; Zobeck M; Mzikamanda R; Chintagumpala M; Allen C; Nuchtern JG; Borgstein E; Aronson DC; Ozuah N; Nandi B; McAtee CL
    Pediatr Blood Cancer; 2023 May; 70(5):e30242. PubMed ID: 36798020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Realities of Wilms Tumor Burden and Therapy in Ghana.
    Kontchou NT; Amankwah E; Seidu I; Stafman LL; Zhao S; Abrahams AOD; Appeadu-Mensah W; Lovvorn HN; Renner LA
    J Pediatr Surg; 2024 Jul; 59(7):1342-1348. PubMed ID: 38589272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of pre-referral tumor resection in unilateral Wilms tumor: A single-institute experience from a lower middle-income country.
    Khan MS; Maaz AUR; Qazi AQ; Aslam S; Riaz S; Malik AS; Shaheen N
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30760. PubMed ID: 37962283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Wilms tumor.
    Aldrink JH; Heaton TE; Dasgupta R; Lautz TB; Malek MM; Abdessalam SF; Weil BR; Rhee DS; Baertschiger R; Ehrlich PF;
    J Pediatr Surg; 2019 Mar; 54(3):390-397. PubMed ID: 30270120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol.
    Vujanić GM; Gessler M; Ooms AHAG; Collini P; Coulomb-l'Hermine A; D'Hooghe E; de Krijger RR; Perotti D; Pritchard-Jones K; Vokuhl C; van den Heuvel-Eibrink MM; Graf N;
    Nat Rev Urol; 2018 Nov; 15(11):693-701. PubMed ID: 30310143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.